The microenvironment in breast cancer progression: Biology and implications for treatment

Breast Cancer Research

Volumn 13, Issue 6, 2011, Pages

  Place, Andrew E ^a,b,c   Jin Huh, Sung ^a,c,d   Polyak, Kornelia ^a,c,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS MODULATOR; AROMATASE INHIBITOR; COMPLEMENTARY DNA; CXCL14 CHEMOKINE; DENOSUMAB; GELATINASE A; LAMININ; MATRIX METALLOPROTEINASE 14; OXYTOCIN RECEPTOR; SCATTER FACTOR; SONIC HEDGEHOG PROTEIN; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; MATRIX METALLOPROTEINASE;

AUTOCRINE EFFECT; BASEMENT MEMBRANE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CARCINOMA ASSOCIATED FIBROBLAST; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL LOSS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA METHYLATION; DNA MICROARRAY; DOWN REGULATION; EPIGENETICS; FIBROBLAST; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE INDUCTION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; KARYOTYPING; LASER CAPTURE MICRODISSECTION; LEUKOCYTE MIGRATION; MALIGNANT TRANSFORMATION; MYOEPITHELIUM CELL; NEUTROPHIL CHEMOTAXIS; OSTEOCLAST; PARACRINE SIGNALING; PROGNOSIS; REVIEW; SERIAL ANALYSIS OF GENE EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; STROMA CELL; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; ANIMAL; BREAST TUMOR; DISEASE COURSE; EPITHELIUM CELL; FEMALE; GENETICS; LEUKOCYTE; METABOLISM; METASTASIS; PATHOLOGY;

ANIMALS; BREAST NEOPLASMS; DISEASE PROGRESSION; EPITHELIAL CELLS; FEMALE; FIBROBLASTS; GENE EXPRESSION PROFILING; HUMANS; LEUKOCYTES; MATRIX METALLOPROTEINASES; NEOPLASM METASTASIS; PROGNOSIS; TUMOR MICROENVIRONMENT;

EID: 80755127904     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2912     Document Type: Review

References (67)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300. 10.3322/caac.20073, 20610543.
2. Sakakura T, Nishizuka Y, Dawe CJ. Mesenchyme-dependent morphogenesis and epithelium-specific cytodifferentiation in mouse mammary gland. Science 1976, 194:1439-1441. 10.1126/science.827022, 827022.
3. Howlett AR, Bissell MJ. The influence of tissue microenvironment (stroma and extracellular matrix) on the development and function of mammary epithelium. Epithelial Cell Biol 1993, 2:79-89.
4. Petersen OW, Ronnov-Jessen L, Howlett AR, Bissell MJ. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci USA 1992, 89:9064-9068. A published erratum appears in Proc Natl Acad Sci USA 1993, 90:2556, 10.1073/pnas.89.19.9064, 50065, 1384042.
5. Maller O, Martinson H, Schedin P. Extracellular matrix composition reveals complex and dynamic stromal-epithelial interactions in the mammary gland. J Mammary Gland Biol Neoplasia 2010, 15:301-318. 10.1007/s10911-010-9189-6, 20811805.
6. Hanahan D, Weinberg R. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. 10.1016/j.cell.2011.02.013, 21376230.
7. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986, 315:1650-1659. 10.1056/NEJM198612253152606, 3537791.
8. Polyak K. Breast cancer: origins and evolution. J Clin Invest 2007, 117:3155-3163. 10.1172/JCI33295, 2045618, 17975657.
9. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med 2004, 350:1430-1441. 10.1056/NEJMra031301, 15070793.
10. Espina V, Liotta LA. What is the malignant nature of human ductal carcinoma in situ?. Nat Rev Cancer 2011, 11:68-75. 10.1038/nrc2950, 21150936.
11. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, Schnitt S, Sellers WR, Polyak K. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004, 6:17-32. 10.1016/j.ccr.2004.06.010, 15261139.
12. Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res 2009, 11:R7. 10.1186/bcr2222, 2687710, 19187537.
13. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348. 10.1016/j.cell.2005.02.034, 15882617.
14. Qiu W, Hu M, Sridhar A, Opeskin K, Fox S, Shipitsin M, Trivett M, Thompson ER, Ramakrishna M, Gorringe KL, Polyak K, Haviv I, Campbell IG. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet 2008, 40:650-655. 10.1038/ng.117, 18408720.
15. Hu M, Yao J, Cai L, Bachman KE, van den Brule F, Velculescu V, Polyak K. Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet 2005, 37:899-905. 10.1038/ng1596, 16007089.
16. Hu M, Yao J, Carroll DK, Weremowicz S, Chen H, Carrasco D, Richardson A, Violette S, Nikolskaya T, Nikolsky Y, Bauerlein EL, Hahn WC, Gelman RS, Allred C, Bissell MJ, Schnitt S, Polyak K. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 2008, 13:394-406. 10.1016/j.ccr.2008.03.007, 18455123.
17. Xing F, Saidou J, Watabe K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci 2010, 15:166-179. 10.2741/3613, 2905156, 20036813.
18. Jedeszko C, Victor BC, Podgorski I, Sloane BF. Fibroblast hepatocyte growth factor promotes invasion of human mammary ductal carcinoma in situ. Cancer Res 2009, 69:9148-9155. 10.1158/0008-5472.CAN-09-1043, 2789178, 19920187.
19. Tyan SW, Kuo WH, Huang CK, Pan CC, Shew JY, Chang KJ, Lee EY, Lee WH. Breast cancer cells induce cancer-associated fibroblasts to secrete hepatocyte growth factor to enhance breast tumorigenesis. PLoS One 2011, 6:e15313. 10.1371/journal.pone.0015313, 3020942, 21249190.
20. Worthley DL, Ruszkiewicz A, Davies R, Moore S, Nivison-Smith I, Bik To L, Browett P, Western R, Durrant S, So J, Young GP, Mullighan CG, Bardy PG, Michael MZ. Human gastrointestinal neoplasia-associated myofibroblasts can develop from bone marrow-derived cells following allogeneic stem cell transplantation. Stem Cells 2009, 27:1463-1468. 10.1002/stem.63, 19492298.
21. Elkabets M, Gifford AM, Scheel C, Nilsson B, Reinhardt F, Bray MA, Carpenter AE, Jirström K, Magnusson K, Ebert BL, Pontén F, Weinberg RA, McAllister SS. Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest 2011, 121:784-799. 10.1172/JCI43757, 3026724, 21266779.
22. Shin SY, Nam JS, Lim Y, Lee YH. TNFalpha-exposed bone marrow-derived mesenchymal stem cells promote locomotion of MDA-MB-231 breast cancer cells through transcriptional activation of CXCR3 ligand chemokines. J Biol Chem 2010, 285:30731-30740. 10.1074/jbc.M110.128124, 2945567, 20650898.
23. Goldstein RH, Reagan MR, Anderson K, Kaplan DL, Rosenblatt M. Human bone marrow-derived MSCs can home to orthotopic breast cancer tumors and promote bone metastasis. Cancer Res 2010, 70:10044-10050. 10.1158/0008-5472.CAN-10-1254, 21159629.
24. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-563. 10.1038/nature06188, 17914389.
25. Direkze NC, Jeffery R, Hodivala-Dilke K, Hunt T, Playford RJ, Elia G, Poulsom R, Wright NA, Alison MR. Bone marrow-derived stromal cells express lineagerelated messenger RNA species. Cancer Res 2006, 66:1265-1269. 10.1158/0008-5472.CAN-05-3202, 16452177.
26. Chabottaux V, Noel A. Breast cancer progression: insights into multifaceted matrix metalloproteinases. Clin Exp Metastasis 2007, 24:647-656. 10.1007/s10585-007-9113-7, 17968664.
27. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, Yamauchi M, Gasser DL, Weaver VM. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906. 10.1016/j.cell.2009.10.027, 2788004, 19931152.
28. Barker HE, Chang J, Cox TR, Lang G, Bird D, Nicolau M, Evans HR, Gartland A, Erler JT. LOXL2-mediated matrix remodeling in metastasis and mammary gland involution. Cancer Res 2011, 71:1561-1572. 10.1158/0008-5472.CAN-10-2868, 21233336.
29. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002, 420:860-867. 10.1038/nature01322, 2803035, 12490959.
30. McDaniel SM, Rumer KK, Biroc SL, Metz RP, Singh M, Porter W, Schedin P. Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis. Am J Pathol 2006, 168:608-620. 10.2353/ajpath.2006.050677, 1606507, 16436674.
31. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006, 6:24-37. 10.1038/nrc1782, 16397525.
32. Man YG, Sang QX. The significance of focal myoepithelial cell layer disruptions in human breast tumor invasion: a paradigm shift from the "protease-centered" hypothesis. Exp Cell Res 2004, 301:103-118. 10.1016/j.yexcr.2004.08.037, 15530847.
33. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens LM. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009, 16:91-102. 10.1016/j.ccr.2009.06.018, 2778576, 19647220.
34. Schedin P, O'Brien J, Rudolph M, Stein T, Borges V. Microenvironment of the involuting mammary gland mediates mammary cancer progression. J Mammary Gland Biol Neoplasia 2007, 12:71-82. 10.1007/s10911-007-9039-3, 17318269.
35. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001, 193:727-740. 10.1084/jem.193.6.727, 2193412, 11257139.
36. Aharinejad S, Paulus P, Sioud M, Hofmann M, Zins K, Schafer R, Stanley ER, Abraham D. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res 2004, 64:5378-5384. 10.1158/0008-5472.CAN-04-0961, 15289345.
37. Knutson KL, Dang Y, Lu H, Lukas J, Almand B, Gad E, Azeke E, Disis ML. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neutransgenic mice. J Immunol 2006, 177:84-91.
38. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, Green AR. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011, 29:1949-1955. 10.1200/JCO.2010.30.5037, 21483002.
39. McAllister SS, Gifford AM, Greiner AL, Kelleher SP, Saelzler MP, Ince TA, Reinhardt F, Harris LN, Hylander BL, Repasky EA, Weinberg RA. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008, 133:994-1005. 10.1016/j.cell.2008.04.045, 18555776.
40. Qian B, Deng Y, Im JH, Muschel RJ, Zou Y, Li J, Lang RA, Pollard JW. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One 2009, 4:e6562. 10.1371/journal.pone.0006562, 2721818, 19668347.
41. Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, Shipley JM, Senior RM, Shibuya M. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002, 2:289-300. 10.1016/S1535-6108(02)00153-8, 12398893.
42. Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM, Karin M. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011, 470:548-553. 10.1038/nature09707, 21326202.
43. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.
44. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, Chi JT, van de Rijn M, Botstein D, Brown PO. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004, 2:E7. 10.1371/journal.pbio.0020007, 314300, 14737219.
45. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sørlie T, Dai H, He YD, van't Veer LJ, Bartelink H, van de Rijn M, Brown PO, van de Vijver MJ. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005, 102:3738-3743. 10.1073/pnas.0409462102, 548329, 15701700.
46. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Hallett M, Park M. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008, 14:518-527. 10.1038/nm1764, 18438415.
47. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, André S, Piccart M, Campone M, Brain E, Macgrogan G, Petit T, Jassem J, Bibeau F, Blot E, Bogaerts J, Aguet M, Bergh J, Iggo R, Delorenzi M. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 2009, 15:68-74. 10.1038/nm.1908, 19122658.
48. Bergamaschi A, Tagliabue E, Sørlie T, Naume B, Triulzi T, Orlandi R, Russnes HG, Nesland JM, Tammi R, Auvinen P, Kosma VM, Ménard S, Børresen-Dale AL. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol 2008, 214:357-367. 10.1002/path.2278, 18044827.
49. Toussaint J, Durbecq V, Altintas S, Doriath V, Rouas G, Paesmans M, Bedard P, Haibe-Kains B, Tjalma WA, Larsimont D, Piccart M, Sotiriou C. Low CD10 mRNA expression identifies high-risk ductal carcinoma in situ (DCIS). PLoS One 2010, 5:e12100. 10.1371/journal.pone.0012100, 2938371, 20856894.
50. Paulsson J, Sjoblom T, Micke P, Ponten F, Landberg G, Heldin CH, Bergh J, Brennan DJ, Jirstrom K, Ostman A. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 2009, 175:334-341. 10.2353/ajpath.2009.081030, 2708819, 19498003.
51. Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, Kleer CG, Brody JR, Lisanti MP. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 2009, 174:2023-2034. 10.2353/ajpath.2009.080873, 2684168, 19411448.
52. Kang H, Watkins G, Parr C, Douglas-Jones A, Mansel RE, Jiang WG. Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res 2005, 7:R402-410. 10.1186/bcr1022, 1175055, 15987445.
53. Alvarez RH. Present and future evolution of advanced breast cancer therapy. Breast Cancer Res 2010, 12(Suppl 2):S1. 3005721, 21172071.
54. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239. 10.1016/j.ccr.2009.01.021, 19249681.
55. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231. 10.1016/j.ccr.2009.01.027, 2874829, 19249680.
56. Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009, 15:167-170. 10.1016/j.ccr.2009.02.007, 19249675.
57. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011, 305:487-494. 10.1001/jama.2011.51, 21285426.
58. Allen M, Louise Jones J. Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol 2011, 223:162-176.
59. Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell 2005, 7:513-520. 10.1016/j.ccr.2005.05.024, 15950901.
60. Holen I, Coleman RE. Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Res 2010, 12:214. 10.1186/bcr2769, 3046431, 21176176.
61. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010, 28:5132-5139. 10.1200/JCO.2010.29.7101, 21060033.
62. Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C, Squadrito ML, Segura I, Li X, Knevels E, Costa S, Vinckier S, Dresselaer T, Åkerud P, De Mol M, Salomäki H, Phillipson M, Wyns S, Larsson E, Buysschaert I, Botling J, Himmelreich U, Van Ginderachter JA, De Palma M, Dewerchin M, Claesson-Welsh L, Carmeliet P. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2011, 19:31-44. 10.1016/j.ccr.2010.11.009, 21215706.
63. DeNardo D, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madder SF, WM G, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirstrom K, West BL, Coussens LM. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Disc 2011,
64. Pasquier E, Kavallaris M, Andre N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010, 7:455-465. 10.1038/nrclinonc.2010.82, 20531380.
65. Weaver VM, Lelievre S, Lakins JN, Chrenek MA, Jones JC, Giancotti F, Werb Z, Bissell MJ. beta4 integrin-dependent formation of polarized threedimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2002, 2:205-216. 10.1016/S1535-6108(02)00125-3, 2788997, 12242153.
66. Hiscox S, Jordan NJ, Jiang W, Harper M, McClelland R, Smith C, Nicholson RI. Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions. Endocr Relat Cancer 2006, 13:1085-1099. 10.1677/erc.1.01270, 17158755.
67. Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA. Targeting tumorassociated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 2006, 116:1955-1962. 10.1172/JCI26532, 1481657, 16794736.